



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BIOMARK CONTRIBUTES IN SCIENTIFIC PUBLICATION

Vancouver, British Columbia – (September 26, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article spermidine/spermine N1-acetyltransferase-1 as a diagnostic biomarker in human cancer has been published in the peer-reviewed journal *Future Science OA*.

Rashid Ahmed, President and CEO, says, “We are extremely excited to have worked with a great team of clinicians, scientists and researchers to realize this important publication. It provides confirmation that one of our technology platforms has an important clinical application in the cancer biomarker space. We would like to thank each of the contributing members of the team and express our sincere gratitude to all supporting organizations that made this possible.”

“BioMark is looking forward to publishing additional peer reviewed papers in the near term on significant discoveries that it has invested resources over the past few years. BioMark’s technology platform will be appreciated by both clinicians and researchers focused on introducing disruptive technology to help better manage cancer,” says Rashid.

The paper is available through open access at <https://www.future-science.com/doi/full/10.4155/fsoa-2018-0077>. BioMark encourages subscription to Future Science for individuals and institutions interested in keeping abreast of new developments in biotechnology and medicine.

About Future Science OA

Future Science and Newlands Press, imprints of Future Science Group, focus on applied science and intellectual property issues in R&D. The journals and eBooks take readers through the pharmaceutical R&D pipeline – from drug discovery, delivery, pharmacokinetics and analytical techniques, through to commentary and analysis on patent and IP issues. The flagship gold open access journal, *Future Science OA*, also embraces the importance of publishing all good-quality research, and covers all areas of biotechnology and medicine, as well as topics in biological, life and physical sciences that are of relevance to human health.

Future Science Journals

Future Science journals provide research professionals worldwide with a unique source of objective cutting-edge information on the most exciting emerging trends in their field of endeavour.

Access to publications is possible via print and online subscriptions or via pay-per-view purchase via the website (for more information, see [Subscriptions and Pricing](#)).

Contact:

[Laura Dormer](#), Editorial Director

Future Science Group,
Unitec House,
2 Albert Place,
London,
N3 1QB, UK

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark is available under its profile on the SEDAR website www.sedar.com and on the CSE website <https://thecse.com/>.

For further information on BioMark, please Contact:

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
Tel. 604-370-0779
Email: info@biomarkdiagnostics.com

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.